Leanne Ward

Leanne Ward

Co-Applicant

Professor of Pediatrics and Tier 1 Clinical Research Chair in Pediatric Bone Disorders at uOttawa | Medical Director of the CHEO Genetic and Metabolic Bone Disease Clinic

Scientific Director of the Ottawa Pediatric Bone Health Research Group | Pediatric Endocrinologist at CHEO


NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research

Email Leanne

Research Interests: children, osteoporosis, osteogenesis imperfecta, bisphosphonate therapy, skeletal dysplasias, bone health, fractures, bone density, glucocorticoid-induced osteoporosis, x-linked hypophosphatemia, achondroplasia, duchenne muscular dystrophy and hypophospha

Academic web profile
Google Scholar profile

Biography

Dr. Leanne Ward is a Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa where she holds a Tier 1 Research Chair in Pediatric Bone Disorders. Dr. Ward is also cross-appointed to the Department of Surgery given strong clinical and research ties to the Division of Orthopedics. She is the Scientific Director of The Ottawa Pediatric Bone Health Research Group, The Medical Director of the Pediatric Osteology Clinic at the Children’s Hospital of Eastern Ontario (CHEO), and a pediatric endocrinologist-osteologist in the CHEO Division of Endocrinology. In 2014, she founded The Canadian Consortium for Children’s Bone Health, a national, multi-disciplinary network of clinicians and scientists that fosters health professional education and research in childhood-onset bone disorders (bonescanada.org). She is also a Steering Committee Member of the International Society of Children’s Bone Health (ISCBH) and the Founder and Director of the Canadian Alliance for Rare Disorders o the Skeleton. 

 

Dr. Ward’s research program is dedicated to the diagnosis and treatment of childhood-onset bone disorders including skeletal dysplasias (i.e. osteogenesis imperfecta and achondroplasia), genetic forms of rickets, hypophosphatasia and osteoporosis due to chronic illnesses (i.e. childhood cancer and Duchenne muscular dystrophy). The Ward lab has a particular focus on therapeutic trials in childhood-onset bone disorders, emphasizing skeletal health outcomes quantified through central skeletal imaging, and the study of novel drugs to mitigate the functional consequences of rare bone diseases. The Ward lab’s signature is local-to-global collaborative engagement with clinicians, researchers and the patient community in key areas that span orthopedics, genetics, radiology, endocrinology, dentistry, audiology, allied health, biomedical statistics and clinical trial operations.   

 

Dr. Ward has held sustained funding from the Canadian Institutes of Health Research since 2003, published over 300 book chapters, abstracts and manuscripts, and delivered over 130 international invited speaking engagements. She works closely with patient advocacy groups to promote patient education and access to rare disease care, including the Canadian Organization for Rare Disorders, The Canadian Osteogenesis Imperfecta Society, The Canadian XLH Network, Parent Project Muscular Dystrophy, Defeat Duchenne Canada and Soft Bones Canada. In 2019, Dr. Ward was named a Fellow of the American Society of Bone and Mineral Research, an award in recognition of significant lifetime contributions to bone and mineral science.  

 


Recent Publications

Minisola, S, Jan de Beur, SM, Carpenter, TO, Dahir, KM, Zanchetta, MB, Ward, L et al.. Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review. Calcif Tissue Int. 2026.117 (1) PMID:42573821

Tobin, RA, Dang, UJ, Hagerty, L, Ward, LM, Rooman, R, Konopka, KH et al.. Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy. Sci Rep. 2026.16 (1) PMID:42547787

Clemens, PR, Berglund, A, Schiava, M, James, MK, McDermott, MP, Bushby, K et al.. Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial. Neurology. 2026.107 (5)e218498 PMID:42531535

Filler, G, Babalola, F, Cowan, A, Khan, T, Ward, L. Prolonged neonatal phosphate retention and transient hypercalcemia following antenatal Burosumab exposure: a pharmacovigilance alert. Ther Adv Drug Saf. 2026.17 20420986261450017 PMID:42454021

Nasomyont, N, Appel, A, Apkon, S, Hoskin, J, Surampudi, PN, Truba, N et al.. Navigating sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy: Current standards of care and future directions. J Neuromuscul Dis. 2026. 22143602261454423 PMID:42439098

Mah, JK, Lochmüller, H, Ward, L, Selby, K, Gonorazky, H, Sbrocchi, AM et al.. Expanding Vamorolone Treatment Access for Canadians with Duchenne Muscular Dystrophy. Can J Neurol Sci. 2026. 1-4 PMID:42438401

Savarirayan, R, Hoover-Fong, J, Irving, M, Arundel, P, de Bergua, JM, Campeau, PM et al.. Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia. N Engl J Med. 2026. PMID:42370681

Clemens, PR, Berglund, A, Schiava, M, James, MK, McDermott, MP, Bushby, K et al.. Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial. Neurology. 2026.107 (1)e214756 PMID:42202243

Wood, CL, Babalola, F, Benjamin, RW, Lam, C, McAdam, L, Nicolau, S et al.. Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. Muscle Nerve. 2026.74 (2)433-439 PMID:42178495

Capasso, A, Arpaia, C, Panicucci, C, Gulli, C, Villa, M, Repetto, A et al.. Vertebral fractures and muscle function in glucocorticoid-treated individuals with Duchenne muscular dystrophy: a cohort study. Osteoporos Int. 2026. PMID:41991651

See more on PubMed